MFN2 and type 2 diabetes mellitus: Thus, it reverses the changes observed in PBMCs from type 2 diabetic patients, who are characterized by down-regulation of MFN2, PINK1, PARKIN, and LAMP-2 genes at the mRNA and protein level.